The National Institutes of Health (NIH) awarded a firm fixed price contract to Vivitide LLC, a manufacturer of laboratory supplies, custom peptide synthesis, monoclonal antibodies, and modified peptides. The $7,000 contract is a call order under a Blanket Purchase Agreement (BPA) to provide reagents and supplies related to the "TAS NEP ARRAY TIER 2" program. The contract was awarded on a competitive basis without a small business set-aside and has a completion date of June 11, 2010....
This is a firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Vivitide LLC (doing business as New England Peptide) for the provision of biomaterials. The contract has a ceiling value of $12,500.00 and was awarded on August 21, 2015 with a completion date of September 20, 2015. The contract is not designated as a set-aside. Vivitide LLC is a for-profit limited liability company that...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Vivitide LLC, a manufacturer of laboratory supplies and peptides. The $8,250.00 contract is for the delivery of 96 crude peptides per plate in a 96-well single tube format. The award was not set aside for any specific business category. Vivitide LLC, also doing business as New England Pepdite, has previously...
Vivitide LLC, operating under the business name New England Peptide, was awarded a firm fixed price purchase order valued at $5,650 by a civilian federal agency with a Pacific West Area designation on January 26, 2015. The contract calls for delivery of three affinity purified antibody packages, with an ultimate completion date of April 23, 2015. The place of performance is located in Pullman, Washington. This contract was awarded without set-aside provisions. Vivitide LLC specializes in the...
The U.S. government awarded a $5,770 firm fixed price purchase order to Vivitide LLC (doing business as New England Peptide) on May 31, 2016, for the delivery of 3X affinity purified antibody packages including Oncorhyncin II, Beta Defensin, and Hepcidin, with dry ice included for shipment. The contract was completed on June 2, 2016, and performance took place in Gardner, Massachusetts. This was a civilian acquisition with no small business set-aside designation. Vivitide LLC is a specialized...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to Vivitide LLC, a for-profit limited liability company that manufactures laboratory supplies and provides custom peptide synthesis, monoclonal antibodies, and modified peptides to the federal government. The contract has a ceiling value of $17,000.00 and is a Firm Fixed Price BPA Call. It was awarded on October 25, 2010 with a period of performance through November 30, 2010. The contract...
This is a cost-plus-fixed-fee task order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Polypeptide Laboratories San Diego, LLC, doing business as Polypeptide Labs. The contract, valued at $595,094.00, is for the synthesis and distribution of opioid and related peptides over a one-year period of performance from February 15, 2025, to February 14, 2026. This task order is part of a larger $2,781,317...
This federal contract award, valued at $200,532.62, was issued by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Polypeptide Laboratories San Diego, LLC, a for-profit biotechnology and pharmaceutical research company. The contract is for the synthesis and distribution of opioid and related peptides, which supports critical biomedical research initiatives. This award is associated with a larger $2,781,317 Indefinite Delivery...
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a firm fixed-price purchase order contract to Peptide 2.0 Inc., doing business as Peptide 20 Inc., for the provision of custom HIV peptides. The contract has a ceiling value of $12,801.20 and an ultimate completion date of September 1, 2017. Peptide 2.0 Inc. is a minority-owned, for-profit business that specializes in custom peptide synthesis and...
The federal contract award is for peptide synthesis services in support of the National Institutes of Health (NIH). New England Peptide LLC was awarded an indefinite delivery/indefinite quantity (IDIQ) blanket purchase agreement (BPA) call against the NIH BPA for Peptide Synthesis and Related Services. The prime contractor will provide peptide synthesis and related services to NIH on an as-needed basis from its place of performance in Bethesda, Maryland. The contract start date was February 2,...
Vivitide LLC (doing business as New England Peptide) was awarded a $34,160 firm fixed price purchase order by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health under the Department of Health and Human Services. The contract, awarded on September 30, 2020, with an ultimate completion date of September 29, 2022, calls for the generation and characterization of modified peptides and the generation of monoclonal antibodies specifically recognizing these modified peptides. The work will be performed in Gardner, Massachusetts. No small business set-aside designation was applied to this competitive procurement.
Vivitide LLC is an established provider of laboratory supplies and custom peptide synthesis services to federal agencies, with particular expertise in supporting drug discovery and preclinical development activities. The company has maintained an ongoing relationship with multiple components of the National Institutes of Health, including the National Institute on Aging, National Institute of Allergy and Infectious Diseases, and National Institute of Child Health and Human Development, as well as the Centers for Disease Control and Prevention. This award reflects NIDA's continuing need for specialized peptide and antibody development services to support its drug abuse research mission.